In general, our experiments recommended the requirement to more discreetly score TIMP1 as a biomarker and therapeutic target, in order to develop the new antibodies for GBM exploration and prevention, with the hope of providing new ideas for clinical diagnosis and treatment of GBM patients and effectively improving sufferer prognosis. The gene discussed is TIMP1; the disease is glioblastoma.